Novo Nordisk signals plans for Wegovy vials

Novo Nordisk has told Reuters it plans to add a vial presentation of Wegovy to its lineup, following a path Eli Lilly already took with its rival weight-loss drug Zepbound ^[1]. The company said, "We are exploring various device presentations for Wegovy, including vials - some are launching this year, others are coming in the future" ^[1]. As of September 2026, no Wegovy vial appears on the US drug label ^[1].

Wegovy, the brand name for semaglutide, was first approved in June 2021 for chronic weight management in adults with obesity or overweight who also have a related condition such as high blood pressure, type 2 diabetes, or high cholesterol, used alongside diet and exercise ^[1]. In 2024, the label expanded to include adults with cardiovascular disease ^[1]. Late last year, the FDA approved a once-daily oral version of Wegovy at 25 mg, making it the first GLP-1 drug approved in pill form for weight management and the third overall formulation of the drug, after the original injectable pens ^[1].

Lilly has already moved in the vial direction with Zepbound, its tirzepatide drug for obesity. The company began selling single-dose vials in 2.5 mg and 5 mg strengths in 2024, then added 7.5 mg and 10 mg vials in 2025 ^[1][2][3]. Vials are generally seen as a lower-cost, higher-supply alternative to prefilled pens, which is part of why Lilly rolled them out as demand for tirzepatide grew ^[1].

Separately, retailers have been working to lower out-of-pocket costs for both Wegovy and Novo's diabetes drug Ozempic. Meijer, a Midwest grocery and pharmacy chain, is now accepting Novo's NovoCare savings program, which offers the two lowest-dose injection pens for $199 a month for the first two months if prescriptions are filled by March 31, 2026 ^[1]. After that introductory period, most doses rise to $349 a month, and the highest Ozempic dose costs $499 a month ^[1]. The oral version of Wegovy is priced as low as $149 a month through the program, with insured patients potentially paying co-pays as low as $25, and no insurance is required to use the coupon ^[1].

Why it matters for patients

A vial option for Wegovy could eventually offer patients a different way to access the drug, similar to how Zepbound vials have functioned for tirzepatide users, but the sources do not specify pricing, dosing, or timing for a Wegovy vial ^[1]. Because no such vial exists yet on the US label, current Wegovy patients still rely on injectable pens or the newer oral tablet ^[1]. Cost remains a major factor in access to GLP-1 drugs, and retailer programs like the one at Meijer show one way manufacturers and pharmacies are trying to make these drugs more affordable outside insurance coverage, though savings amounts and eligibility rules vary and are time-limited ^[1].

Separately, researchers continue to study whether GLP-1 drugs have effects beyond weight loss and blood sugar control. A study published in PeerJ found that these drugs lower markers of chronic inflammation, including CRP and TNF-alpha, both indirectly through weight loss and directly through binding immune cell receptors ^[1][4]. The strongest reductions were seen in patients treated for at least 36 weeks, and long-acting drugs such as dulaglutide showed larger effects than short-acting ones ^[1]. A separate meta-analysis of more than 6,000 patients, published in Frontiers in Endocrinology, found consistent reductions in CRP compared with placebo and other diabetes pills, though effects on another marker, IL-6, were mixed across studies ^[1]. These findings raise questions about broader health effects of GLP-1 drugs, but they do not change current approved uses or dosing.

What happens next

Novo Nordisk has not given a specific date for when a Wegovy vial might reach the US market, saying only that some device changes are planned for this year and others further out ^[1]. As of the article's publication in mid-February 2026, no Wegovy vial had appeared on the US label ^[1]. The Meijer discount pricing for Wegovy and Ozempic pens requires prescriptions to be filled by March 31, 2026, to qualify for the lowest introductory rate ^[1].